Regulation of plasminogen activator inhibitor-1 secretion by urokinase and tissue plasminogen activator in rat epithelioid-type smooth muscle cells

British Journal of Haematology

Volumn 117, Issue 1, 2002, Pages 151-158

  Lau, Herbert K F ^a   Ho, Joanne ^a  

^a ST MICHAEL'S HOSPITAL   (Canada)

Author keywords

PAI 1; Signal transduction; Smooth muscle cells; tPA; uPA

Indexed keywords

MITOGEN ACTIVATED PROTEIN KINASE; PLASMINOGEN ACTIVATOR INHIBITOR 1; PROTEIN KINASE C; PROTEIN TYROSINE KINASE; RAF PROTEIN; TISSUE PLASMINOGEN ACTIVATOR; UROKINASE;

ANIMAL CELL; ARTICLE; CONTROLLED STUDY; DOWNSTREAM PROCESSING; DRUG INHIBITION; ENZYME ACTIVATION; ENZYME PHOSPHORYLATION; ENZYME RELEASE; EPITHELIOID CELL; NONHUMAN; PATHOPHYSIOLOGY; PLASMINOGEN ACTIVATION; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN INTERACTION; RAT; REGULATORY MECHANISM; SIGNAL TRANSDUCTION; SMOOTH MUSCLE FIBER;

1-METHYL-3-ISOBUTYLXANTHINE; 8-BROMO CYCLIC ADENOSINE MONOPHOSPHATE; ANIMALS; BUCLADESINE; CARBAZOLES; CELLS, CULTURED; CYCLIC AMP-DEPENDENT PROTEIN KINASES; ENZYME INHIBITORS; FLAVONOIDS; GENISTEIN; INDOLES; ISOQUINOLINES; MAP KINASE SIGNALING SYSTEM; MUSCLE, SMOOTH, VASCULAR; PHOSPHODIESTERASE INHIBITORS; PHOSPHORYLATION; PLASMINOGEN ACTIVATOR INHIBITOR 1; PROTEIN KINASE C; PROTEIN-TYROSINE KINASES; PYRROLES; RATS; SIGNAL TRANSDUCTION; SRC-FAMILY KINASES; STILBENES; SULFONAMIDES; TISSUE PLASMINOGEN ACTIVATOR; URINARY PLASMINOGEN ACTIVATOR;

EID: 0036223530     PISSN: 00071048     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2141.2002.03402.x     Document Type: Article

References (62)

1. Use and specificity of genistein as inhibitor of protein-tyrosine kinases
2. Angiotensin II type 1 receptor signals through Raf-1 by a protein kinase C-dependent, Ras-independent mechanism
3. The human receptor for urokinase plasminogen activator
4. Plasminogen activator expression in rat arterial smooth muscle cells depends on their phenotype and is modulated by cytokines
5. Urokinase plasminogen activator receptor, β2-integrins, and Src-kinases within a single receptor complex of human monocytes
6. Blocking signaling through the Gp130 receptor chain by interleukin-6 oncostatin M inhibits PC-3 cell growth and sensitizes the tumor cells to ectoposide and cisplatin-mediated cytotoxicity
7. Protein kinase C-α participates in FcγR-mediated phagocytosis in macrophages
8. Signaling through the p38 and p42/44 mitogen-activated families of protein kinases in pancreatic beta-cell proliferation
9. Induction of cell migration by pro-urokinase binding to its receptor: Possible mechanism for signal transduction in human epithelial cells
10. Role of diacylglycerol-regulated protein kinase C isotypes in growth factor activation of the Raf-1 protein kinase
11. Urokinase but not tissue plasminogen activator mediates arterial neointima formation in mice
12. Protein kinase C-mediated serine phosphorylation directly activates Raf-1 in murine hematopoietic cells
13. An endothelial cell receptor for plasminogen-tissue plasminogen activator (t-PA). II. Annexin II-mediated mediated enhancement of t-PA dependent plasminogen activation
14. Protein kinase C regulates chon-drogenesis of mesenchymes via mitogen-activated protein kinase signaling
15. Smooth muscle cells express urokinase during mitogenesis and tissue plasminogen activator during migration in injured rat carotid artery
16. Effect of thrombin on release of plasminogen activator inhibitor-1 from cultured primate arterial smooth muscle cells
17. Structure-activity relationships among monoterpene inhibitors of protein isoprenylation and cell proliferation
18. Urokinase-type and tissue-type plasminogen activators as growth factors of human fibroblasts
19. Phosphotidylinositol-3-kinase is required for insulin-like growth factor-I induced vascular smooth muscle cells proliferation and migration
20. The Jak/Stat pathway and urokinase receptor signalling in human aortic vascular smooth muscle cells
21. Vascular smooth muscle cells potentiate plasmin generation by both urokinase and tissue plasminogen activator-dependent mechanisms: Evidence for a specific tissue plasminogen activator receptor on these cells
22. Binding of tissue plasminogen activator to human monocytes and monocytoid cells
23. Plasminogen activator inhibitor activity in diabetic and non-diabetic survivors of myocardial infarction
24. The endothelial cell tissue plasminogen activator receptor
25. Angiotensin-converting enzyme inhibition suppresses plasminogen activator inhibitor-1 expression in the neointima of balloon-injured rat aorta
26. Plasminogen activator inhibitor type 1 and tissue inhibitor of metalloproteinases-2 increase after arterial injury in rats
27. Tissue plasminogen activator is a potent mitogen for human aortic smooth muscle cells
28. Distinct mechanisms mediate the initial and sustained phases of integrin-mediated activation of the Raf/MEK/mitogen-activated protein kinase cascade
29. i-coupled receptors
30. The role of plasminogen activation in smooth muscle cell migration after arterial injury
31. Activation of mitogen-activated protein kinases and phospholipase D in A7r5 vascular smooth muscle cells
32. Regulation of protein kinase Cβ1 by two protein-tyrosine kinases, Btk and Syk
33. Angiopoietin-1 regulates endothelial cell survival through the phosphatidylinositol 3′-kinase/Akt signal transduction pathway
34. G appha(i-2) mediates renal LLC-PK1 growth by a Raf-independent activation of p42/p44 MAP kinase
35. Protein kinase C (alpha) activates RAF-1 by direct phosphorylation
36. Cleavage of structural proteins during assembly of head bacteriophage T4
37. Regulation of proteolytic enzymes and inhibitors in two smooth muscle cell phenotypes
38. Hypofibrinolysis in patients with hypercoagulability: The roles of urokinase and plasminogen activator inhibitor
39. Ligation of CD53/OX44, a tetraspan antigen, induces homotypic adhesion mediated by specific cell-cell interactions
40. 2+ channels in adult bullfrog sympathetic neurons by nerve growth factor
41. 'Outside-in' signalling mechanisms underlying CD11b/CD18-mediated NADPH oxidase activation in human adherent blood eosinophils
42. Factors responsible for impaired fibrinolysis in obese subjects and NIDDM patients
43. Opportunities for pharmacological intervention in the ras pathway
44. Binding of urokinase-type plasminogen activator to its receptor in MCF-7 cells activates extracellular signal-regulated kinases 1 and 2 which is required for increased cellular motility
45. Inhibition of mast cell FcR1-mediated signaling and effector function by the Syk-selective inhibitor, piceatannol
46. Rat aortic smooth muscle cells isolated from different layers and at different times after endothelial denudation show distinct biological features in vitro
47. Quantification of plasminogen activators and their inhibitors in the aortic vessel wall in relation to the presence and severity of atherosclerotic disease
48. Cellular receptor for urokinase plasminogen activator
49. Syk activation initiates downstream signaling events during human polymorphonuclear leukocyte phagocytosis
50. G proteins and phospholipase C mediate thrombin-induced generation of plasminogen activator inhibitor-1 from vascular smooth muscle cells
51. Glutamine metabolism stimulates intestinal cell MAPKs by a cAMP-inhibitable, Raf-independent mechanism
52. Perillic acid inhibits Ras/MAP kinase-driven IL-2 production in human T lymphocytes
53. Protein kinase activity-dependent inhibition of urokinase-type plasminogen activator gene transcription by cyclic AMP in human pre-B lymphoma cell line RC-K8
54. Activation of protein kinase C β gene expression by gonadotropin-releasing hormone in αT3-1 cell line
55. vβ3 binding to vitronectin
56. Plasma urokinase antigen and plasminogen activator inhibitor-1 antigen levels predict angiographic coronary restenosis
57. The urokinase-type plasminogen activator receptor mediates tyrosine phosphorylation of focal adhesion proteins and activation of mitogen-activated protein kinase in cultured endothelial cells
58. FcepsilonR1-mediated antigen endocytosis turns interferon-gamma-treated mouse mast cells from inefficient into potent antigen-presenting cells
59. Protein kinase C activates the MEK-ERK pathway in a manner independent of Ras and dependent on Raf
60. A dual inhibitor of platelet-derived growth factor beta-receptor and Src kinase activity potently interferes with motogenic and mitogenic responses to PDGF in vascular smooth muscle cell. A novel candidate for prevention of vascular remodeling
61. Thrombin stimulates expression of tissue-type plasminogen activator and plasminogen activator inhibitor type 1 in cultured human vascular smooth muscle cells
62. Growth factor induced MEK activation is primarily mediated by an activator different from c-raf